The present invention relates to a biomarker composition for diagnosing colon cancer or predicting prognosis of colon cancer metastasis, the biomarker composition comprising NCK-associated protein 1 (NCKAP1) as an active ingredient. Specifically, a novel colon cancer target candidate has been discovered through a mass gene expression analysis in blood of a human body colon cancer tissue transplantation mouse model, and experimental verification thereon has been performed through the inhibition of target candidate gene expression in colon cancer cell lines. As a result, it has been observed that NCKAP1 is overexpressed in blood and tissues of colon cancer patients, and that migration, invasion and metastasis of cancer cells by the inhibition of NCKAP1 are inhibited. Also, the possibility of NCKAP1 as a new colon cancer target has been confirmed. Therefore, a colon cancer diagnosis and gene expression inhibitor using the expression level of NCKAP1 can be effectively used as an active ingredient for a pharmaceutical composition for treating cancer or inhibiting cancer metastasis.
展开▼
